The more recent advancements in HCL technology have allowed for automated insulin delivery based on glucose trends, resulting in improved overall diabetes control [21–23], reduced risk of hypoglycemia [21,23–26], and decreased disease burden [21–23,25–27]. The gene discussed is INS; the disease is Hypoglycemia.